Holen Sie sich die Stockscreener-App
4.93
0.60%
-0.03
Handel nachbörslich:
4.93
Schlusskurs vom Vortag:
$4.96
Offen:
$4.94
24-Stunden-Volumen:
465.70K
Relative Volume:
0.27
Marktkapitalisierung:
$318.33M
Einnahmen:
$317.00K
Nettoeinkommen (Verlust:
$-53.47M
KGV:
-2.6085
EPS:
-1.89
Netto-Cashflow:
$-49.31M
1W Leistung:
+0.00%
1M Leistung:
+19.23%
6M Leistung:
+53.11%
1J Leistung:
+165.05%
1-Tages-Spanne:
$4.88
$5.05
1-Wochen-Bereich:
$4.72
$5.24
52-Wochen-Spanne:
$1.10
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Firmenname
Immuneering Corp
Sektor
Branche
Telefon
617-500-8080
Adresse
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
4.93 | 320.27M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 12.04B | 3.95B | 3.34B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Eingeleitet | Leerink Partners | Outperform |
| 2024-12-13 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | Herabstufung | Jefferies | Buy → Hold |
| 2024-03-15 | Bestätigt | Needham | Buy |
| 2024-03-15 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | Eingeleitet | Needham | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-04-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-04-19 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | Eingeleitet | Mizuho | Neutral |
| 2023-02-03 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-04-01 | Eingeleitet | Oppenheimer | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Immuneering Corp Aktie (IMRX) Neueste Nachrichten
Sanofi Invests $18.96 Million in Immuneering Corporation $IMRX - MarketBeat
Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
What is Immuneering Corporation’s valuation compared to sector2025 Performance Recap & Long-Term Safe Investment Plans - mfd.ru
Empery Asset Management, LP Reduces Stake in Immuneering Corp - GuruFocus
Thomas Schall Buys 21,645 Shares of Immuneering (NASDAQ:IMRX) Stock - Defense World
Immuneering (NASDAQ:IMRX) Insider Harold Eugene Brakewood Purchases 5,250 Shares of Stock - MarketBeat
Immuneering’s (IMRX) chief business officer buys $24,990 in stock By Investing.com - Investing.com Australia
Immuneering’s (IMRX) chief business officer buys $24,990 in stock - Investing.com
Insider Buying: Immuneering (NASDAQ:IMRX) Director Purchases 21,645 Shares of Stock - MarketBeat
Immuneering director Schall buys $101k in shares By Investing.com - Investing.com India
Immuneering director Schall buys $101k in shares - Investing.com
Immuneering Corporation (NASDAQ:IMRX) Short Interest Update - Defense World
Immuneering Corporation (NASDAQ:IMRX) Sees Significant Growth in Short Interest - MarketBeat
Insider Buying: Brett Hall Acquires Additional Shares of Immunee - GuruFocus
Hedge Fund and Insider Trading News: Ken Griffin, Bill Ackman, Michael Burry, Warren Buffett, Aurelius Capital Management, Balyasny Asset Management, Jain Global, Saba Capital Management, Bain Capital, Immuneering Corp (IMRX), Cloudflare Inc (NET) - Insider Monkey
Director of Immuneering Picks Up 1.8% More Stock - Yahoo Finance
Insider Buying: Leah Neufeld Acquires Additional Shares of Immuneering Corp (IMRX) - GuruFocus
Immuneering chief people officer Neufeld buys $10,905 in IMRX By Investing.com - Investing.com Nigeria
Immuneering chief people officer Neufeld buys $10,905 in IMRX - Investing.com
Looking Into Immuneering Corp's Recent Short Interest - Sahm
Immuneering director Feinberg buys $86k in shares By Investing.com - Investing.com Nigeria
Immuneering director Feinberg buys $86k in shares - Investing.com
Iridian Asset Management LLC CT Makes New $1.93 Million Investment in Immuneering Corporation $IMRX - MarketBeat
Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition - Yahoo Finance
Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next - Yahoo Finance
Why Immuneering (IMRX) Is Down 29.7% After Phase 2a Pancreatic Data Versus Historical Benchmarks And Phase 3 Plan - simplywall.st
Assessing Immuneering (IMRX) Valuation After Positive Phase 2a Pancreatic Cancer Trial Progress - simplywall.st
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - Sahm
Risk Hedge: Can Immuneering Corporation stock deliver strong Q4 earningsJuly 2025 Big Picture & Safe Capital Allocation Plans - ulpravda.ru
Can Immuneering Corporation stock outperform in 2025 bull marketJuly 2025 Momentum & Free Technical Pattern Based Buy Signals - ulpravda.ru
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data (NASDAQ:IMRX) - Seeking Alpha
Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink - TipRanks
Stock market today: S&P 500, Dow Jones futures decline — AZZ, Northrop Grumman, Immuneering in focus - MSN
Is Immuneering Corporation stock gaining market shareJuly 2025 Fed Impact & Community Trade Idea Sharing Platform - Улправда
IMRX Stock Closed Over 20% Higher Today: Here’s Why - Asianet Newsable
Immuneering Pancreatic Cancer Study Reports Promising Survival Results, Yet Shares Decline - Bitget
Why Is Immuneering Stock Trading Lower Today?Immuneering (NASDAQ:IMRX) - Benzinga
Immuneering: Phase 2a Strength of Atebimetinib in First-Line Pancreatic Cancer Supports Buy Rating Despite Competitive Overhang - TipRanks
Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update - TechStock²
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED) - Benzinga
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED) - Benzinga
Finanzdaten der Immuneering Corp-Aktie (IMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):